| Literature DB >> 11470997 |
R Eiselt1, T L Domanski, A Zibat, R Mueller, E Presecan-Siedel, E Hustert, U M Zanger, J Brockmoller, H P Klenk, U A Meyer, K K Khan, Y A He, J R Halpert, L Wojnowski.
Abstract
The genetic component of the inter-individual variability in CYP3A4 activity has been estimated to be between 60% and 90%, but the underlying genetic factors remain largely unknown. A study of 213 Middle and Western European DNA samples resulted in the identification of 18 new CYP3A4 variants, including eight protein variants. A total of 7.5% of the population studied was found to be heterozygous for one of these variants. In a bacterial heterologous expression system, two mutants, R130Q and P416L, did not result in detectable P450 holoprotein. One mutant, T363M, expressed at significantly lower levels than wild-type CYP3A4. G56D, V170I, D174H and M445T were not significantly different when compared with wild-type CYP3A4 in expression or steroid hydroxylase activity. L373F displayed a significantly altered testosterone metabolite profile and a four-fold increase in the Km value for 1'-OH midazolam formation. The results suggest a limited contribution of CYP3A4 protein variants to the inter-individual variability of CYP3A4 activity in Caucasians. Some variants may, however, play a role in the atypical response to drugs or altered sensitivity to carcinogens.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11470997 DOI: 10.1097/00008571-200107000-00008
Source DB: PubMed Journal: Pharmacogenetics ISSN: 0960-314X